To lay the foundation for a future randomized clinical trial to demonstrate the clinical efficacy of neoadjuvant PD-1 blockade, we conducted a pilot study to examine the safety and feasibility of using the combination of neoadjuvant PD-1 blockade with chemotherapy in a small group of patients with resectable ESCC. Here, PDCD1 is linked to esophageal squamous cell carcinoma.